MED1 Ventures

Chief Executive Officer Tim Willis and Chief Technology Officer Steve Bacich, both co-founders, drive investment decisions. Willis brings over 30 years of ophthalmology operating experience, while Bacich has more than 20 years in medical devices focused on women's health. The firm does not disclose an independent investment committee.

The firm originates products internally by identifying unmet clinical needs and developing solutions through its in-house engineering and clinical team. It does not describe a traditional inbound deal-sourcing funnel from founders or brokers. Portfolio companies are formed around MED1-developed products rather than acquired as existing startups.

The firm targets early-stage development, covering seed through startup phases. Investments are tied to a product lifecycle — development, regulatory clearance, and early commercialization — with a stated exit horizon of 18 to 48 months.

MED1 Ventures lists dedicated managing partners for Greater China, Southeast Asia, and Europe, alongside its Raleigh headquarters. The website also references a global market focus and regulatory clearances in over 30 countries achieved by the management team at prior ventures.